<SEC-DOCUMENT>0001628280-23-015415.txt : 20230504
<SEC-HEADER>0001628280-23-015415.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504064256
ACCESSION NUMBER:		0001628280-23-015415
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230504
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		23886314

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20230504.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:18deaaec-b931-4d8c-8db7-4ac605c98d6f,g:8cf2589c-c8d1-4c32-82c3-c2f3a13251fe,d:362d99337d004db8a3908cfe42b517d8--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20230504</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF80L2ZyYWc6MWUxYWZlZmEzZGIxNDVlOGEzMGQ3ZjQ0NzA4Mjg2OTcvdGFibGU6MWFmODBlM2JlMTk2NGRjYTg5NjA1YmEwOGNlNjVlOGEvdGFibGVyYW5nZToxYWY4MGUzYmUxOTY0ZGNhODk2MDViYTA4Y2U2NWU4YV8wLTEtMS0xLTc1MDEy_d845aba6-58a8-41f2-bfd7-79579109cc4f">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF80L2ZyYWc6MWUxYWZlZmEzZGIxNDVlOGEzMGQ3ZjQ0NzA4Mjg2OTcvdGFibGU6MWFmODBlM2JlMTk2NGRjYTg5NjA1YmEwOGNlNjVlOGEvdGFibGVyYW5nZToxYWY4MGUzYmUxOTY0ZGNhODk2MDViYTA4Y2U2NWU4YV8xLTEtMS0xLTc1MDEy_4ae61edc-0430-4139-8d75-85f640bfb8be">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20230504.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i362d99337d004db8a3908cfe42b517d8_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.068%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"></td><td style="width:48.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YjI1MjI4MDFiMWM1NDc3MjkzN2FmOWJiYTBkOTJlYzkvdGFibGVyYW5nZTpiMjUyMjgwMWIxYzU0NzcyOTM3YWY5YmJhMGQ5MmVjOV8wLTEtMS0xLTc1MDEy_eeebbf38-b088-47a4-a88c-4d65e59d3b7b">8-K</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8yMTg_ceedc049-36ec-4047-bbf1-c6bf025077c2">May 4, 2023</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.603%"><tr><td style="width:1.0%"></td><td style="width:22.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.600%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6NTVlMjEzMmNjZGE0NDYzNTk0YmU0YmMxOWFiNGZhYTIvdGFibGVyYW5nZTo1NWUyMTMyY2NkYTQ0NjM1OTRiZTRiYzE5YWI0ZmFhMl8xLTAtMS0xLTc1MDEy_7f241a4e-5c2f-4ab0-8cc9-1cffa7f52c9f">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.793%"><tr><td style="width:1.0%"></td><td style="width:32.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YWEyZWMwYTA3NGQ0NDg5MGIwOWZhMDAwNTZiMjY4ODkvdGFibGVyYW5nZTphYTJlYzBhMDc0ZDQ0ODkwYjA5ZmEwMDA1NmIyNjg4OV8wLTAtMS0xLTc1MDEy_02a44277-5b86-48b5-a7d0-72fca3e9f87f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YWEyZWMwYTA3NGQ0NDg5MGIwOWZhMDAwNTZiMjY4ODkvdGFibGVyYW5nZTphYTJlYzBhMDc0ZDQ0ODkwYjA5ZmEwMDA1NmIyNjg4OV8wLTItMS0xLTc1MDEy_9b450f4a-6543-4be6-9d48-0f9043f37dfc">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YWEyZWMwYTA3NGQ0NDg5MGIwOWZhMDAwNTZiMjY4ODkvdGFibGVyYW5nZTphYTJlYzBhMDc0ZDQ0ODkwYjA5ZmEwMDA1NmIyNjg4OV8wLTQtMS0xLTc1MDEy_7c56515a-4b06-4574-ba24-6456e5f10ac7">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.373%"><tr><td style="width:1.0%"></td><td style="width:20.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8wLTAtMS0xLTc1MDEy_0df0b830-9982-4cbc-bf96-005b91f46d0b">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8wLTEtMS0xLTc1MDEy_9278b7d6-2ab6-45d5-af90-930e73c48bd4">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8xLTAtMS0xLTc1MDEy_416bfd44-2036-4b5a-8d1a-44720a952bd0">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8xLTEtMS0xLTc1MDEy_3877af69-31fd-4962-8079-ee89e7d0e085">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8xLTMtMS0xLTc1MDEy_13aa98c0-8616-4800-adc6-53d8c13134ff">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjQ3_47e91c38-c726-449b-92c2-74abbdde5e71">857</ix:nonNumeric>) <ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjUz_af84f287-c6c7-4816-975e-d2aa19629f9a">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_______________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjU1_45d4a4d3-78df-45e9-a621-47e0aa11240c">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjQ4_ce395da9-d16d-46f4-a845-b6de4aedba2e">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjUw_bcb85e7d-c0ca-49e6-8084-891a37a5b267">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjU4_5936d55b-2d3d-4918-9c34-a86768a5f593">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.252%"><tr><td style="width:1.0%"></td><td style="width:34.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6NGQ1NjFlNjdmMTIxNGFkNGIxMjc2YWY5MmNhNGJjN2IvdGFibGVyYW5nZTo0ZDU2MWU2N2YxMjE0YWQ0YjEyNzZhZjkyY2E0YmM3Yl8xLTAtMS0xLTc1MDEy_1f7007b5-7251-4a6f-9d90-5195701678f4">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6NGQ1NjFlNjdmMTIxNGFkNGIxMjc2YWY5MmNhNGJjN2IvdGFibGVyYW5nZTo0ZDU2MWU2N2YxMjE0YWQ0YjEyNzZhZjkyY2E0YmM3Yl8xLTItMS0xLTc1MDEy_2deb7b97-760a-4df9-9d3f-272bf267a25c">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6NGQ1NjFlNjdmMTIxNGFkNGIxMjc2YWY5MmNhNGJjN2IvdGFibGVyYW5nZTo0ZDU2MWU2N2YxMjE0YWQ0YjEyNzZhZjkyY2E0YmM3Yl8xLTQtMS0xLTc1MDEy_d8e3d506-b8bb-47c1-aec8-ef6fd4b2c60f">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#167;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#167;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">240.12b-2 of this chapter).          Emerging growth company&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjUx_da5feac2-0921-4b97-9f59-f7b12b4491f1">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i362d99337d004db8a3908cfe42b517d8_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 4, 2023, X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results and other business highlights for the first quarter ended March 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="padding-left:4.5pt"><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The information furnished under this Item 2.02 in this Current Report of Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="a991pressreleasedatedmay42.htm">Press Release of X4 Pharmaceuticals, Inc. dated May 4, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i362d99337d004db8a3908cfe42b517d8_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  May 4, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adam Mostafa</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam Mostafa</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991pressreleasedatedmay42.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0a8cfd240d484d6f8417d16046f7389e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div><img alt="x4logoa.jpg" src="x4logoa.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:118px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:102%">X4 Pharmaceuticals Reports First-Quarter 2023 Financial </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:102%">Results and Provides Corporate Update</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Company to host webinar event on May 16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> presenting new clinical data from the  4WHIM Phase 3 trial&#59; oral presentation to follow on May 21</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> at the </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">2023 </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clinical Immunology Society (CIS) Annual Meeting</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">U.S. NDA submission of mavorixafor for WHIM syndrome on track for early 2H 2023</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Presentation of data from ongoing Phase 2 chronic neutropenia trial and clarity on </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">regulatory path forward anticipated in 2Q&#47;3Q 2023</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:102%">Conference call to be hosted today at</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:102%"> 8&#58;30 a.m. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:102%">ET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">BOSTON &#8211; May 4, 2023&#8212; X4 Pharmaceuticals Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Nasdaq&#58; XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023 and highlighted key upcoming expected milestones. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;This is an exciting time at X4 as we look forward to delivering on several expected major milestones throughout the rest of 2023,&#8221; said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. &#8220;As we recently announced, we will be presenting additional data on secondary endpoints, including results on</font><font style="background-color:#ffffff;color:#3d3d3d;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> infection burden among other outcomes metrics,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> from the Phase 3 trial of mavorixafor in those diagnosed with WHIM syndrome at the upcoming annual meeting of the Clinical Immunology Society&#59; a May 16 company webinar with clinical experts will be followed by an oral data presentation on May 21 at the conference. Additionally, we continue to anticipate submission of our first U.S. New Drug Application for mavorixafor early in the second half of the year. We are also continuing to advance mavorixafor through a Phase 2 clinical trial in people with certain Chronic Neutropenic disorders and expect to provide clinical and regulatory path updates in the second or third quarter of this year.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Recent and Key Anticipated Upcoming Milestones</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Additional Data from the Phase 3 4WHIM Trial to be Presented at Upcoming CIS Meeting&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">In late 2022, the company announced that its Phase 3 clinical trial evaluating once-daily, oral mavorixafor in people with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome met its primary endpoint and first key secondary endpoint, with mavorixafor achieving statistically significant and clinically relevant longer times above threshold levels for both absolute neutrophil and absolute lymphocyte counts versus placebo and demonstrating good tolerability in the trial.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Subsequently, X4 announced that its submitted late-breaker abstract entitled &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Results of a Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Syndrome&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> was accepted for oral presentation at the Annual Meeting of the Clinical Immunology Society (CIS), which is taking place May 18-21, 2023, in St. Louis, MO.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">Dr. Raffaele Badolato, Professor of Pediatrics at the University of Brescia (Italy) and an investigator in the 4WHIM clinical trial, will present at 11&#58;30 am CT on Sunday, May 21. Although the session will only be accessible live to conference attendees, X4 will post the slides on its website concurrent with the presentation.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">X4 to Host May 16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-style:italic;font-weight:700;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%"> Webinar Highlighting Infection Data from Phase 3 4WHIM Clinical Trial&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">The company will be hosting a virtual event to present and discuss new data from the 4WHIM Phase 3 clinical trial at 4&#58;00 pm ET on Tuesday, May 16, 2023, following the expected publication of the accepted CIS abstracts. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">New data to be presented during the event will focus on additional secondary endpoints, including the impact of mavorixafor on the rate, severity, and duration of infections, among other outcomes metrics, as measured during the 52-week trial period. Registration for the event can be completed </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">here</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">The event will include commentary from several WHIM patients and from a diverse panel of global clinical experts who manage those with WHIM syndrome and&#47;or certain chronic neutropenic disorders. These experts include&#58;</font></div><div style="padding-left:72pt;text-indent:-23.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:18pt">Charlotte Cunningham-Rundles, MD, PhD</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, The David S. Gottesman Professor, Departments of Medicine and Pediatrics, The Prism Immunology Institute, The Icahn School of Medicine at Mount Sinai&#59;</font></div><div style="padding-left:72pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:18pt">Jean Donadieu, MD, PhD</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, Pediatrician, Hemato oncologic department of Trousseau Hospital, Coordinator of the French Histiocytosis registry, Coordinator of the pediatric branch of the French histiocytosis reference center&#59;</font></div><div style="padding-left:72pt;text-indent:-29.31pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:18pt">Peter E. Newburger, MD</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, Editor, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Pediatric Blood &#38; Cancer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, Professor of Pediatrics and Molecular, Cell, and Cancer Biology, UMass Chan Medical School&#59;</font></div><div style="padding-left:72pt;text-indent:-29.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">iv.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:18pt">Akiko Shimamura, MD, PhD</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, Professor of Pediatrics, Harvard Medical School and Director, Bone Marrow Failure and Myelodysplastic Syndrome Program, Boston Children&#8217;s Hospital&#59; and</font></div><div style="padding-left:72pt;text-indent:-25.73pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">v.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:18pt">Teresa K. Tarrant, MD, FAAAAI</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, Associate Professor of Medicine, Duke University School of Medicine, Director, Clinical Immunology Laboratory DUHS, Vice Chief of Translational Research for Rheumatology and Immunology.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">During the May 16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> event, the company also expects to provide an update on its U.S. regulatory activities in support of its U.S. New Drug Application-submission for mavorixafor for the treatment of WHIM syndrome, which continues to be expected early in the second half of 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Advancing Mavorixafor in Chronic Neutropenic Disorders</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">In September 2022, X4 presented positive data from a Phase 1b clinical trial demonstrating the ability of one dose of oral mavorixafor to increase and normalize absolute neutrophil counts (ANC) in people with idiopathic, cyclic, or congenital chronic neutropenia as monotherapy or administered concurrently with injectable granulocyte colony-stimulating factor (G-CSF). </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">The Phase 1b trial has been expanded into a Phase 2 clinical trial to assess the long-term durability, safety, and tolerability of oral mavorixafor in a larger population with idiopathic, cyclic, or congenital chronic neutropenia.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Participants are currently being enrolled in this Phase 2 trial and X4 anticipates announcing clinical data and clarity on the scope and timing of the expected Phase 3 clinical program for mavorixafor in these Chronic Neutropenic disorders in the second or third quarter of 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">X4 also announced today that its abstract, entitled &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Incidence of Serious Infection Events in People With Chronic Neutropenia&#8212;Analysis of Real-World Data From Patients in the United States</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">,&#8221; was accepted for poster presentation at CIS on Saturday, May 20, 2023 at 1&#58;30 pm CT. This poster will be added to the publications section of the X4 website at the time of the presentation.  </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">First Quarter 2023 Financial Results </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Cash, Cash Equivalents &#38; Restricted Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; X4 had $94.4 million </font><font style="background-color:#ffffff;color:#201f1e;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">in cash, cash equivalents, and restricted cash as of March 31, 2023. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4 believes that it has sufficient funds to support company operations into the second quarter of 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Research and Development (R&#38;D) Expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">were $22.1 million for the first quarter ended March 31, 2023 as compared to $14.1 million for the comparable period in 2022.  R&#38;D expenses for the first quarter ended March 31, 2023 included $0.8 million of certain non-cash expenses and a $5.0 million accrual for an in-licensing milestone payment that the company deems probable of occurring.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Selling, General and Administrative Expenses (SG&#38;A)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $7.2 million for the first quarter ended March 31, 2023 as compared to $7.7 million for the comparable period in 2022. SG&#38;A expenses included $0.8 million of certain non-cash expenses for the first quarter ended March 31, 2023. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Net Loss&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4 reported a net loss of $24.0 million for the first quarter ended March 31, 2023, as compared to $22.0 million for the comparable period in 2022. Net loss included $1.6 million of stock-based compensation expense and a $5.4 million gain for the change in fair value of the company&#8217;s Class C warrant liability for the first quarter ended March 31, 2023. </font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4 will host a conference call and webcast today at 8&#58;30 am ET to discuss these financial results and business highlights. The conference call can be accessed by dialing 1-855-327-6837 from the United States or 1-631-891-4304 internationally, followed by the conference ID&#58; 10021600. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals&#8217; website at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.x4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Following the completion of the call, a webcast replay of the conference call will be available on the website.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About X4 Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on the discovery and development of novel therapies for people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, we believe that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency. Following announcement of positive top-line data from our global, pivotal, 4WHIM Phase 3 clinical trial, we are currently preparing a U.S. regulatory submission seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome. We are also currently evaluating mavorixafor in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following positive results from a Phase 1b clinical trial of mavorixafor in people with congenital, idiopathic, or cyclic neutropenia. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">center of excellence in Vienna, Austria. For more information, please visit our website at &#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.x4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the clinical progress of X4&#8217;s pipeline development programs</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#59; the status of clinical trials, including, without limitation, expectations regarding the data that are being presented, the expected timing of data releases and evaluation, as well as completion of clinical trials and the timing thereof&#59; interactions with regulators and the timing thereof, including the anticipated NDA submission for U.S. regulatory approval of mavorixafor in WHIM&#59; market opportunities for X4&#8217;s product candidates&#59; expectations regarding the potential efficacy and commercial potential of mavorixafor&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and the sufficiency of X4&#8217;s cash resources and expectations regarding X4&#8217;s cash runway</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, on account of uncertainties inherent in the initiation and completion of clinical trials and clinical development&#59; the risk that trials and studies may not have satisfactory outcomes&#59; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results&#59; the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials&#59; the potential adverse effects arising from the testing or use of mavorixafor or other product candidates&#59; the risk that the Food and Drug Administration (FDA) may not support and accept a regulatory submission for mavorixafor, and that X4&#8217;s interactions with the FDA may not have satisfactory outcomes&#59; the risks related to X4&#8217;s ability to raise additional capital&#59; the impacts of general macroeconomic and geopolitical conditions, including the COVID-19 pandemic, the conflict in Ukraine, rising inflation, and uncertain credit and financial markets on X4&#8217;s business, clinical trials and financial position&#59; and other risks and uncertainties, including those described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 21, 2023, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(Tables Follow)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0a8cfd240d484d6f8417d16046f7389e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.883%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,063&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,113&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,664&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of non-financial asset</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,304&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,268&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,304)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,268)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,288&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,016)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,942)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,020)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend due to Class B warrant price reset</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,259)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,020)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,224)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders- basic and diluted </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.72)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding-basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,967&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,737&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,020)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,108)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,512)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,229)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,124)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,595)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,364)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,028&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,108&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,433&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,744&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents </font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,406&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,718&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development incentive receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,158&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,807&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,222&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,677&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,351&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,351&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,844&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,229&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,405&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,586&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58; </font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,992&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,777&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,762&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,034&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,315&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,483&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,324&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, including accretion, net of discount</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,827&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,377&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,603&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,042&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,729&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,535&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,676&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,051&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders' equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,405&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,586&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Daniel Ferry  (investors)   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                     </font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Managing Director, LifeSci Advisors</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                           </font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">daniel&#64;lifesciadvisors.com</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                       </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(617) 430-7576  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                           </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cherilyn Cecchini, M.D. (media)</font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">LifeSci Communications</font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ccecchini&#64;lifescicomms.co</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20230504.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18deaaec-b931-4d8c-8db7-4ac605c98d6f,g:8cf2589c-c8d1-4c32-82c3-c2f3a13251fe-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20230504" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20230504">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xfor-20230504_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18deaaec-b931-4d8c-8db7-4ac605c98d6f,g:8cf2589c-c8d1-4c32-82c3-c2f3a13251fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_ef237803-616f-4850-938f-e1d100b17ad5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b368a696-4704-4cb8-91fc-1efcd54bc5d6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_35339c29-7d00-499c-9e03-da1beb898c45_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f9beebd9-3d36-499c-bcf6-2e0ddac57826_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b00388c5-e765-4294-8609-cce0ac57471d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2413d912-e169-4ce4-bb6c-6e309f89a97f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_faa1fb46-e0a2-452c-a92d-1047625c226e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6a8695f3-3844-48bb-a41f-e5f6741364a1_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_15c7d2d9-421b-42e0-b68c-8509e4411d9b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5e2912c3-be9d-40b9-b29d-55aafe172fcb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_13561dff-4d44-4f0d-b7a5-632191bb4835_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_55169968-59cb-47c6-a4ca-4ca60d5dbd4e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_aed9471f-5e5c-4a0c-bd10-8dbfa9e9b93c_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_56a74ab2-b3f0-4bf6-a390-af466db997aa_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1cc591f4-2cc4-4a3c-b6d3-0c13e1e1fb89_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8106b666-44f8-443d-9590-1e1b707fc985_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_ff7567c9-8a99-4c22-9b7e-514db3ed35a9_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2cd9b89c-3899-48ad-92c1-f23628c722ca_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0577be9f-092e-4bfc-8b6f-fb63777c4982_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b742c8d0-220b-469d-9af7-cc7fa5a3fd5b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b9abd7d9-ac1f-42c7-998a-8319b542cf73_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5c7325c0-a2c8-47c5-8572-0f1fa9bb4bab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_66e9d61f-f030-436e-91c2-6078df003395_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_62dcaa8c-b9cc-4966-a8f1-17b3e4e9db02_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xfor-20230504_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18deaaec-b931-4d8c-8db7-4ac605c98d6f,g:8cf2589c-c8d1-4c32-82c3-c2f3a13251fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20230504.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_74bcb3d3-c05b-47e7-859f-81147a0f9f57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_DocumentType_74bcb3d3-c05b-47e7-859f-81147a0f9f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fc9735ad-2553-4fca-a9d2-f1ef8e5e8e9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_DocumentPeriodEndDate_fc9735ad-2553-4fca-a9d2-f1ef8e5e8e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_41c6e958-7d3c-4e93-be35-102875c71ee5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityRegistrantName_41c6e958-7d3c-4e93-be35-102875c71ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3b3dc03d-5a28-4f75-9fb1-110d6c4199cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3b3dc03d-5a28-4f75-9fb1-110d6c4199cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_22303556-5977-4f5d-b8bb-96a557e9ab3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityFileNumber_22303556-5977-4f5d-b8bb-96a557e9ab3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e206b66d-0c69-4a9c-ade7-961af97540d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityTaxIdentificationNumber_e206b66d-0c69-4a9c-ade7-961af97540d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ae793ac2-f0a9-40e5-b782-95dff691aa0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityAddressAddressLine1_ae793ac2-f0a9-40e5-b782-95dff691aa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_aa40c5b9-965f-4781-a00f-75dc1effd10f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityAddressAddressLine2_aa40c5b9-965f-4781-a00f-75dc1effd10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_59cd92b4-047b-4195-ad05-c9198e8ee100" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityAddressCityOrTown_59cd92b4-047b-4195-ad05-c9198e8ee100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_210fb0a7-6c72-48d2-99c7-3a068f001a0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityAddressStateOrProvince_210fb0a7-6c72-48d2-99c7-3a068f001a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f51623b2-241a-4184-bd5a-10ddd5a6223a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityAddressPostalZipCode_f51623b2-241a-4184-bd5a-10ddd5a6223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_295ac0eb-e5ad-4342-836e-461c3a415e50" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_CityAreaCode_295ac0eb-e5ad-4342-836e-461c3a415e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3057ba4f-88e3-4357-ae89-48a20431b511" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_LocalPhoneNumber_3057ba4f-88e3-4357-ae89-48a20431b511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_c5108f67-98b4-4007-a2f2-e4283d79c632" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_WrittenCommunications_c5108f67-98b4-4007-a2f2-e4283d79c632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a28ab75b-5509-4b91-9380-84baf27b4691" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_SolicitingMaterial_a28ab75b-5509-4b91-9380-84baf27b4691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_adf62de6-3ab5-42a3-818d-3ca5077a0bf6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_PreCommencementTenderOffer_adf62de6-3ab5-42a3-818d-3ca5077a0bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_82a3c0a2-4eaa-40ef-b0c7-561faeba74e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_82a3c0a2-4eaa-40ef-b0c7-561faeba74e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9de81d02-ab07-43b2-a680-36a844685521" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_Security12bTitle_9de81d02-ab07-43b2-a680-36a844685521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e19925cb-ce37-4aca-b867-01bea4cfaca3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_TradingSymbol_e19925cb-ce37-4aca-b867-01bea4cfaca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8de65d1e-a41b-44fa-ac9e-1c76b68cc429" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_SecurityExchangeName_8de65d1e-a41b-44fa-ac9e-1c76b68cc429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d0cb1efc-1858-4c2b-bbce-3222b776ed7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityEmergingGrowthCompany_d0cb1efc-1858-4c2b-bbce-3222b776ed7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_31d51375-c2df-480d-8c18-3c903e846ade" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityExTransitionPeriod_31d51375-c2df-480d-8c18-3c903e846ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f621f74b-3749-488a-96c8-fd2130b46dc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_EntityCentralIndexKey_f621f74b-3749-488a-96c8-fd2130b46dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_bbcebcc9-03e0-4bcf-9323-966002232a54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f296cc6-a252-496e-a7db-a9f7b73c15e7" xlink:to="loc_dei_AmendmentFlag_bbcebcc9-03e0-4bcf-9323-966002232a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>x4logoa.jpg
<TEXT>
begin 644 x4logoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !; '8# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**\O\
MBS\7]1^%M]:[_#HU#3;I<17BW13$@ZHPV'!QR.>1GT-:4Z<JLN6.YA6K0P\/
M:5'9'J%%?./_  UV_P#T*P_\#O\ [77KWPO^)-E\3?#O]H6\?V6ZB?RKFS+[
MC$W;G R".0<>OH:VJ8:K2CS36AS4,?AL1/DI2N_G^IV%%%175U#8VLMQ<2+#
M!"ADDD<X55 R23Z 5RGH$M%?/&H?M<0QWUPEEX<:YM%<K%-)=[&D4'ABNPXS
MUQFI]#_:@U'Q)K%II>G>#_M%[=.(XXQ??F2?+X &23V KM^I5[7<?Q1Y/]J8
M1OE4]?1_Y'T!138]_EKY@428&X*<C/?%.KB/6"BN5^)'Q LOAOX9EU6[7SY2
MPCM[56VM-(>B@]AC))[ 5XW_ ,-=O_T*P_\  [_[7733PU6LN:"T."OCL/AI
M<E65G\_T/HZBO/?A'\3K_P"*%K>WTFAC2]/@811S&X\PRR=6 &T< 8R?4X]:
M]"K&<)4Y.,MSJI585H*I#9A1114&H5C>+_"EAXV\/7>CZE'OMKA<;A]Z-ARK
MJ>Q!YK9HIIN+NB914TXR5TSX$\9>$;_P-XBN]&U%?W\!RDBC"S1G[KK[$?D<
MCM6I\+?B%<?#?Q9!J2;I+&3$-[;K_P M(L]0/[R]1^([U]0?&SX61_$CP[OM
M55-<L@7M)#QO'>)CZ-CCT.#ZU\9S0R6\TD,T;131L4>-QAE8'!!'8@U]30K1
MQ5)J6_4_/<9AIY=B%*#TW3_0_0O3[^WU2QM[RTF6XM;A%EBE0Y#J1D$?A7SK
M^TO\5/M$C^#M+F_=H0VI2H>IZB'^1;\!ZUQOP]^.VH^!/!6J:(J-<2E<Z9*W
M(MF8_."#U49W >N1T/'F$LLD\KRRNTLLC%WD<Y9F)R23W)-<N'P7LZKE/9;'
MHX[-E6P\:=+1RW\O+Y_D- +$  LQ. JC))]!7UW\!/A&/ >C_P!JZG"/[?OD
M&Y6ZVT9Y$8]SP6]\#M7"?LW_  B^V20^+]8A_<1G.FV\@^^P_P"6Q'H/X?S]
M*^E:QQV*O^ZA\_\ (Z<HP'*EB:JUZ?Y_Y!4=Q<16=O+//(L4,2EWD<X55 R2
M3Z 5)7SM^TU\4=JGP=IDWS, ^I2(>B]5A_'@M[8'<UYE&BZTU!'OXK$QPM)U
M9?+S9YO\1O&&H_&KX@P6^F1O-;>9]ETRVZ9!/,C>A;&XGLH'I78^(M!^$'[/
M.DV<GQ'U>._UBZ3>EKB21GQU,<$?.T'C<W'TZ5D_LLVD%Q\2IY90#+;Z?(\.
M>S%T4D?@3^=?%_[36N:EX@_: \>W&JN[W$&JS6<:N?\ 5PQ-LB0>@V@'_@1/
M>O1QM:5!JC2T21Z7 W#=#B3$U*V-EHM7^6E[K\'9*R/TH^!_Q\^%WQ&A30?
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MP]G4M;<T/#M_%I7B'2KV?=Y-K=PSR;!EMJN&.!ZX%?4;?M4^"U4DQ:K@#/\
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9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139964526917184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>xfor-20230504_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20230504.xsd" xlink:type="simple"/>
    <context id="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF80L2ZyYWc6MWUxYWZlZmEzZGIxNDVlOGEzMGQ3ZjQ0NzA4Mjg2OTcvdGFibGU6MWFmODBlM2JlMTk2NGRjYTg5NjA1YmEwOGNlNjVlOGEvdGFibGVyYW5nZToxYWY4MGUzYmUxOTY0ZGNhODk2MDViYTA4Y2U2NWU4YV8wLTEtMS0xLTc1MDEy_d845aba6-58a8-41f2-bfd7-79579109cc4f">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF80L2ZyYWc6MWUxYWZlZmEzZGIxNDVlOGEzMGQ3ZjQ0NzA4Mjg2OTcvdGFibGU6MWFmODBlM2JlMTk2NGRjYTg5NjA1YmEwOGNlNjVlOGEvdGFibGVyYW5nZToxYWY4MGUzYmUxOTY0ZGNhODk2MDViYTA4Y2U2NWU4YV8xLTEtMS0xLTc1MDEy_4ae61edc-0430-4139-8d75-85f640bfb8be">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YjI1MjI4MDFiMWM1NDc3MjkzN2FmOWJiYTBkOTJlYzkvdGFibGVyYW5nZTpiMjUyMjgwMWIxYzU0NzcyOTM3YWY5YmJhMGQ5MmVjOV8wLTEtMS0xLTc1MDEy_eeebbf38-b088-47a4-a88c-4d65e59d3b7b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8yMTg_ceedc049-36ec-4047-bbf1-c6bf025077c2">2023-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6NTVlMjEzMmNjZGE0NDYzNTk0YmU0YmMxOWFiNGZhYTIvdGFibGVyYW5nZTo1NWUyMTMyY2NkYTQ0NjM1OTRiZTRiYzE5YWI0ZmFhMl8xLTAtMS0xLTc1MDEy_7f241a4e-5c2f-4ab0-8cc9-1cffa7f52c9f">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YWEyZWMwYTA3NGQ0NDg5MGIwOWZhMDAwNTZiMjY4ODkvdGFibGVyYW5nZTphYTJlYzBhMDc0ZDQ0ODkwYjA5ZmEwMDA1NmIyNjg4OV8wLTAtMS0xLTc1MDEy_02a44277-5b86-48b5-a7d0-72fca3e9f87f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YWEyZWMwYTA3NGQ0NDg5MGIwOWZhMDAwNTZiMjY4ODkvdGFibGVyYW5nZTphYTJlYzBhMDc0ZDQ0ODkwYjA5ZmEwMDA1NmIyNjg4OV8wLTItMS0xLTc1MDEy_9b450f4a-6543-4be6-9d48-0f9043f37dfc">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YWEyZWMwYTA3NGQ0NDg5MGIwOWZhMDAwNTZiMjY4ODkvdGFibGVyYW5nZTphYTJlYzBhMDc0ZDQ0ODkwYjA5ZmEwMDA1NmIyNjg4OV8wLTQtMS0xLTc1MDEy_7c56515a-4b06-4574-ba24-6456e5f10ac7">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8wLTAtMS0xLTc1MDEy_0df0b830-9982-4cbc-bf96-005b91f46d0b">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8wLTEtMS0xLTc1MDEy_9278b7d6-2ab6-45d5-af90-930e73c48bd4">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8xLTAtMS0xLTc1MDEy_416bfd44-2036-4b5a-8d1a-44720a952bd0">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8xLTEtMS0xLTc1MDEy_3877af69-31fd-4962-8079-ee89e7d0e085">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6YzYyNTQ1YTgzMjkzNGU4NzhkYjMwNzdkZTMyMDUxZWEvdGFibGVyYW5nZTpjNjI1NDVhODMyOTM0ZTg3OGRiMzA3N2RlMzIwNTFlYV8xLTMtMS0xLTc1MDEy_13aa98c0-8616-4800-adc6-53d8c13134ff">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjQ3_47e91c38-c726-449b-92c2-74abbdde5e71">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjUz_af84f287-c6c7-4816-975e-d2aa19629f9a">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjU1_45d4a4d3-78df-45e9-a621-47e0aa11240c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjQ4_ce395da9-d16d-46f4-a845-b6de4aedba2e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjUw_bcb85e7d-c0ca-49e6-8084-891a37a5b267">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjU4_5936d55b-2d3d-4918-9c34-a86768a5f593">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6NGQ1NjFlNjdmMTIxNGFkNGIxMjc2YWY5MmNhNGJjN2IvdGFibGVyYW5nZTo0ZDU2MWU2N2YxMjE0YWQ0YjEyNzZhZjkyY2E0YmM3Yl8xLTAtMS0xLTc1MDEy_1f7007b5-7251-4a6f-9d90-5195701678f4">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6NGQ1NjFlNjdmMTIxNGFkNGIxMjc2YWY5MmNhNGJjN2IvdGFibGVyYW5nZTo0ZDU2MWU2N2YxMjE0YWQ0YjEyNzZhZjkyY2E0YmM3Yl8xLTItMS0xLTc1MDEy_2deb7b97-760a-4df9-9d3f-272bf267a25c">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGFibGU6NGQ1NjFlNjdmMTIxNGFkNGIxMjc2YWY5MmNhNGJjN2IvdGFibGVyYW5nZTo0ZDU2MWU2N2YxMjE0YWQ0YjEyNzZhZjkyY2E0YmM3Yl8xLTQtMS0xLTc1MDEy_d8e3d506-b8bb-47c1-aec8-ef6fd4b2c60f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MmQ5OTMzN2QwMDRkYjhhMzkwOGNmZTQyYjUxN2Q4L3NlYzozNjJkOTkzMzdkMDA0ZGI4YTM5MDhjZmU0MmI1MTdkOF8xL2ZyYWc6OWQzNThmOTEzNDAzNDM4ZGFiZDk3MTc0NTg0Mjc5ZGUvdGV4dHJlZ2lvbjo5ZDM1OGY5MTM0MDM0MzhkYWJkOTcxNzQ1ODQyNzlkZV8xNjUx_da5feac2-0921-4b97-9f59-f7b12b4491f1">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !;-:16JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( %LUI%9ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !;-:16)!Z;HJT   #X 0
M&@              @ ',$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !;-:1699!YDAD!  #/ P  $P              @ &Q$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #[$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20230504.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="xfor-20230504.htm">xfor-20230504.htm</File>
    <File>a991pressreleasedatedmay42.htm</File>
    <File>xfor-20230504.xsd</File>
    <File>xfor-20230504_lab.xml</File>
    <File>xfor-20230504_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20230504.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "xfor-20230504.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20230504_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20230504_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20230504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20230504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230504.htm",
      "contextRef": "ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.x4pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230504.htm",
      "contextRef": "ibb577c35d8b343ff865d1529e9fd90ad_D20230504-20230504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-015415-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015415-xbrl.zip
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M1_4EFBR583O^765?>SQPN25B(I60W8J^'T0ANY!!&!7^&?, AJ48_$)ZW+.
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M_3[H0_597,3L@BH,K06THF[6XTXG6:0!W%!DWV%-0<H",_G)4$A$P&#L1X[
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MD_F(<H4\4%H*HE4C0RL.0TIM&<UH&4UH&3-%08!6B4Y*)=9WV3G)S_M8A*D
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MMRU%O&%B2\E%8C[$9^&"F8ZA"Z05E$@II2%MW <^ %'!8[0+^[@"!FOY(+*
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MANPT1T]'%5B6&J8MUKJQR&[B@-I(#L<&C&U+RHF!X;O9QAY<]8]D:?](GK8
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M+1+;!6U>F$!M.3)FW=U7'4J+\[E X\DL%?X! W:2PU/P&QEK"X=X_D/'F%L
M'C3='=R=M]ZK<TO0FS7L\4O.,T]/$]X+4PDQ_.'R!Y$A/GA<\QJF%Z,S6Z*_
M$FZD*&Q$=WL^\]M.8NW!3;K\5<GAU/^1$?C3M1=2I>@X>%H(-F4<:B)+!E;L
M@NJ 30@-\KT@K^&3?\4R4-H&[-+%@D]3G%TK/CSN94U? TU_<(\F=JB]X^]S
M[G&TYS[!O/IN[Z7,^>F&I1<3B6HZ"/GY]/;JM'7^[?ZR=?KESF"7UZUG,DPV
M/>+6S?79^?7=^1DHGNN[FR^79Z?W\!]W]_#7U?GU_1V[N6 W7\]O3^\OX8;<
MSN- G9T5PSOLH>#KHU>F1P$CERJ+9\N,C4\@]CCH24 BDV/\^$'5(Z>""J-1
M:-LYO!^*X^1?3FR)#7 &Q]*C]]-#)SHA24NW*3VJ:>;J\E" %$M*B$3 ;9&=
M?%E?+M*EP\B>O%8_*C8JE9F72T5SJ6MFL58O+_GD[,&:9K'9G'UY^<&6JVL:
M[-PK"S01 H+\^[O*N^2^A#H\'Q/"\G#G(5%7,.L1G9=Y7&*J0=XS;W_QUJ.)
M6\O]'WCSR03C3W14(=98E3AHOB0-B._N>X$0[ KNZX7L')W_J5#8;\9K;T::
M+KI+>S"\5:L3S%B%>QE 7FDS7,R3K=B=D4.R?V:6;V*IRFNGX0WPQ:3#V[*$
MZ'2>VQ5,]E_OGDP O\ECNG%3;E05H#Y>&0L^1KML/T.-+TU['HJ>]8[5\$ON
M1[@#M*Z#.V.TSNCOHYP2_4@59C; O!39CZW ^+8OLG(EEF=9\>OX\BPTM9-Q
M-U NYE0N&Z5Z932%:YGI)32_P#3W1/96B,RL&J:9.R+; >4S'6CE6_FDQ<O=
M3/$R'RU>7BO\*B^VH%/%17YXJV&4J^:"K/4,V:Q+?K_5S:G7JWG;G!V0>]L(
MNO_ G "LW>&J,09V&AA&]K%_9K0.^#T79\V+DO+#6;IA6]XPQ7Y[U/8<U$I'
M[_.S+3L@\K;(IW:/I8])?ZV,9VW3J&ZFRVK<A9QSYBH?&972DK!B[C78(D"X
M,_MJ&N5Z<ZOV=0<$ZW3EDTO!B@V1=*UYVKQPTYAQOJ!<SCGO0(G4A1'+W!')
M;8&8.[*;)$BW8C=W0(!N$3*]H31RZ6$I CO0N/2]@=W=-@U.MXB_:D:YN21,
MV5*$N46;<U!O+*#']L[&W0.(;6QC(%0SIK2H2\N\B/]8T@[?@XQQD%$U2F9]
M*T#&?C?G@8Q'U?)6[.8.B-0M@HQ?5RM&WR8HR5T,=+\QVN6X:%;.'C#N%&!,
M&HKG%A)N'8X 5%@NK0Y'["(PW+H]!6Q8KVW+GNZ  %T.'L)"OS)EG GA"IO9
M$KL>8RJ]Z@BKCD7XE!Z+T ^D1>UD]E[&M6?X[)'CJTE%HUQ;(,=G#QQW$C@R
M'D6!;,>J10((/^P(B%F.> Y-CSJ)KP5<KA=\Y&:9%ZX&F7_>>14KNPV@]W2[
MNW1;+J\P@V1O).R.#SE5EIF.2"^KS0*V2-7M"VV)G=#LM11&+9!:6 $BM/T8
MQ[S+,FGQB>=4*)6*BT0H%Y[VABVK/>'N,.$V%@C&;IAP=T"9;I'E^9W^ T]0
MT^<N):H3]6J(C8:Q 2L=*3NA/W,2YM#= *<0Z4^*K/QPL%FM&4?UQG+U>2M<
MINV+E[P!XJA4C$9EUV@CIUK@D$R,CZLZYW3? 7@#'8!;IW>?V<67F^];T@%X
MJ_K\;D]SWVJQ4:_-VX)V[M>:M6*IN=QK-] S& ?;G.NU/]O-<\O:I$[VK&73
M.Z>NKLOI]O?CW+<N7;)UZ5OPUJZL!/N-N)J>FW0^[9"%@XT+37I[O*-[<MT2
M<ETP$?%5R'67?8VG]I]Q&*EC .G4)SQ"5H*YX"41/?@5_YW.A(Q#=634L/,-
M'I+V2"=?S00:.];WJ6*8I<4K[[?48[=%&U,V2I7ZYKJE[3)>;-%I=N$8YV,_
M/W7>G2/5<89X_MU28F#[DD/KYJ*TML_;?34)75H<\.YQPLLFXXL08#GFW[EB
MFKI1,U=8:+W] ;\=V-.242XOWN]S[7NZRZAC0N1([U&?,?VS(F?'VBH>+%ZE
MDAMIL^^2.47:_%1F6$XDS3:"FP,M:MZKWD*V.L]:]S#?0YTI%7+F]E0$[)'.
M'%M:-8YJ2WI1\B>"M@CL7+I]$"YX:@*V-H-AX!'3Y';!$Q50.!E*1(F_8OG(
M'7+8HN\E $@42 O31?'Z'@Z]^U@K;56'Z3TFFD?5U'.(<7<=$]G""@0/!1I?
M:Q9!.Z9&#\I-HW:T-1U5]M!HGCTU:T:EGD.XN\NXJ#6WV&$\8FW1E9Z'EAH
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MDDY655SD<B=H13;PK(_^%O)^HM]LP)$1<:^,**ID\9=Y"BHE*U"&@WZ]/<[
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M\HO+.D ABA[_M'H),R$IE1PP$D$0BXR#3+ 4Q)3C,.$D$U@]OWB9<862C'#
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MP'>V?9_/Y#HQ1#&,!($(2(B)7G;+&#"&.< R"HG*""6I<IMD'XR/37KK&<,
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MNRO;HMW3JF>)ZU1??JK.RYMB"A.>"B1TVHT@TU]D"!@V+V E(9%Q#*$@S*O
M]=#'V 3[N&ACD&H> X/5L[2U1:AC8<N/IH'+6IT8\B]I[7+0OZ"U9?/7E+-V
MG6HM9EF:^@K\0\'+ZJJLEG7QK[6.&Z?E=5%7=Z>ED--$(KW,YA%@D@@0AXP
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M](,LCG2$Q1@.KW [ML+EP(KM)W&FK]X\VWR2K_Y4QIMG_P-02P,$%     @
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M2P$"% ,4    " !;-:16E%W@*F<"  !N!P  $0              @ 'C.P
M>&9O<BTR,#(S,#4P-"YX<V102P$"% ,4    " !;-:16<U,+1O$*  #X9
M%0              @ %Y/@  >&9O<BTR,#(S,#4P-%]L86(N>&UL4$L! A0#
M%     @ 6S6D5G^D\I<'!P  #34  !4              ( !G4D  'AF;W(M
F,C R,S U,#1?<')E+GAM;%!+!08     !0 % % !  #74      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
